Correlation Between Vaxcyte and Replimune
Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxcyte and Replimune Group, you can compare the effects of market volatilities on Vaxcyte and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Replimune.
Diversification Opportunities for Vaxcyte and Replimune
Very good diversification
The 3 months correlation between Vaxcyte and Replimune is -0.24. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Vaxcyte i.e., Vaxcyte and Replimune go up and down completely randomly.
Pair Corralation between Vaxcyte and Replimune
Given the investment horizon of 90 days Vaxcyte is expected to under-perform the Replimune. But the stock apears to be less risky and, when comparing its historical volatility, Vaxcyte is 2.55 times less risky than Replimune. The stock trades about -0.12 of its potential returns per unit of risk. The Replimune Group is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest 1,028 in Replimune Group on September 3, 2024 and sell it today you would earn a total of 380.00 from holding Replimune Group or generate 36.96% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Vaxcyte vs. Replimune Group
Performance |
Timeline |
Vaxcyte |
Replimune Group |
Vaxcyte and Replimune Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Vaxcyte and Replimune
The main advantage of trading using opposite Vaxcyte and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.Vaxcyte vs. Larimar Therapeutics | Vaxcyte vs. Syndax Pharmaceuticals | Vaxcyte vs. Merus BV | Vaxcyte vs. Sutro Biopharma |
Replimune vs. Nuvalent | Replimune vs. Ventyx Biosciences | Replimune vs. Ascendis Pharma AS | Replimune vs. United Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Complementary Tools
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |